Advaxis, Merck Report Initiation of Enrollment in Phase 1/2 Study of ADXS-PSA in Combo with Anti-PD-1 Therapy
April 08, 2015 at 07:33 AM EDT
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE: MRK), known as ...
